REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
Key facts
- Where
- Qionghai and Shanghai, ChinaSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 80 years old?
Source: NCT06987214, who can take part
Where in China
- Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of MedicineQionghai, ChinaContact: Wen SuTaking people
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Jiayang YanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06987214
- Record updated
- 28 July 2026
- Original description
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.Read full original descriptionShow less
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.
Inclusion: Age 25-80 years; Confirmed diagnosis of bronchiectasis; FEV1 ≥35% predicted; DLCO ≥30% and <80% predicted.
Exclusion: Active malignancy or history of malignancy; Positive serology for HIV, HBV, HCV, or syphilis; Pregnancy, lactation, or plans for pregnancy within 1 year.